796 completed, 231 unknown, 107 terminated, 45 recruiting. 1273 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1273 | Completed 796, Unknown 231, Terminated 107, Recruiting 45, Withdrawn 44, Active not recruiting 23, Not yet recruiting 20, Enrolling by invitation 6, Suspended 1 |
Follow Communicable Diseases: new trials by email Literature Review of Communicable Diseases trials Research Report on Communicable Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-11-09 |
| Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study Field-based LA-CAB/RPV - HIV Infection | Phase 4 | Not yet recruiting | University of North Carolina, Chapel Hill | 40 | 2027-01-01 | 2026-10-26 |
| B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants Bepirovirsen - Hepatitis B | Phase 4 | Not yet recruiting | GlaxoSmithKline | 303 | 2026-12-03 | 2026-11-02 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection - HIV Infections, Opioid Use Disorder | Phase 4 | Not yet recruiting | Duke University | 450 | 2026-12-01 | 2026-11-06 |
| Daily, Weekly, or Event-driven Doxycycline for STI Prevention Among Men Who Have Sex With Men (MSM) Engaging in Chemsex: The DOSE Non-inferiority Trial On demand doxycycline hyclate 200mg, Daily doxycycline hyclate 100mg, Weekly doxycycline hyclate 100mg - Gonorrhea, Chlamydia | Phase 4 | Not yet recruiting | University of California, Los Angeles | 300 | 2026-11-01 | 2026-11-12 |
| Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg - HIV (Human Immunodeficiency Virus), Sleep | Phase 4 | Not yet recruiting | University of Witwatersrand, South Africa | 40 | 2026-10-05 | 2026-10-06 |
| BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies ERVEBO Vaccination - Ebola, Bundibugyo Virus Disease (BVD) | Phase 4 | Recruiting | Epicentre | 20000 | 2026-09-19 | 2026-10-29 |
| Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV Vaginal estradiol tablets, Vaginal moisturizer - Menopausal Complaints, Vaginal Atrophy | Phase 4 | Not yet recruiting | Albert Einstein College of Medicine | 62 | 2026-09-01 | 2026-07-28 |
| ESCUDDO Long Term Follow Up Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine - Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm | Phase 4 | Enrolling by invitation | National Cancer Institute (NCI) | 13700 | 2026-08-11 | 2026-11-12 |
| Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV) Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried - Rabies, HIV Infections | Phase 4 | Recruiting | Liaoning Chengda Biotechnology CO., LTD | 160 | 2026-08-08 | 2026-11-12 |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV Tirzepatide - Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease | Phase 4 | Enrolling by invitation | National Taiwan University Clinical Trial Center | 60 | 2026-06-25 | 2026-07-20 |
| REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE Bictegravir, emtricitabine, and tenofovir alafenamide - HIV -1 Infection, HIV (Human Immunodeficiency Virus) | Phase 4 | Recruiting | CAN Community Health | 200 | 2026-06-17 | 2026-09-03 |
| Menopausal HT for Women Living With HIV (HoT) Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel - HIV Infection, Menopause | Phase 4 | Recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 105 | 2026-04-09 | 2026-05-22 |
| Vitality in Infants Via Azithromycin for Neonates Trial Azithromycin at Baseline, Azithromycin at Day 21, Placebo at Baseline - Neonatal Death, Infectious Disease | Phase 4 | Not yet recruiting | University of California, San Francisco | 4000 | 2026-04-01 | 2025-08-29 |
| Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling - Gonorrhea, Chlamydia | Phase 4 | Recruiting | Westat | 760 | 2026-02-27 | 2026-10-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 60 | 2026-01-11 | 2026-01-16 |
| Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach Tenofovir Alafenamide (TAF), Community-Based Support, Simplified WHO 2024 Criteria - Chronic Hepatitis B, Hepatitis B Virus Infection | Phase 4 | Not yet recruiting | The Task Force for Global Health | 6000 | 2026-01-01 | 2025-12-02 |
Showing 20 of 1273. Sign in to see all of them.
HIV Infections (414) · Acquired Immunodeficiency Syndrome (211) · Hepatitis B, Chronic (190) · Hepatitis C (184) · Hepatitis B (174) · Hepatitis C, Chronic (144) · Papillomavirus Infections (33) · Tuberculosis (27) · Sexually Transmitted Diseases (21) · Lipodystrophy (20) · Liver Cirrhosis (20) · Infections (18) · Chlamydia Infections (17) · Fibrosis (17)
Infections (1255) · Virus Diseases (1206) · Blood-Borne Infections (1160) · RNA Virus Infections (855) · Urogenital Diseases (681) · Genital Diseases (659) · Sexually Transmitted Diseases (636) · Digestive System Diseases (631) · Hepatitis, Viral, Human (623) · Liver Diseases (622) · Sexually Transmitted Diseases, Viral (619) · Hepatitis (611) · Immune System Diseases (581) · Retroviridae Infections (573)
Ribavirin (136) · peginterferon alfa-2a (124) · Tenofovir (101) · Lamivudine (87) · entecavir (70) · Ritonavir (60) · Emtricitabine (51) · efavirenz (48) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (44) · Raltegravir Potassium (42) · Sofosbuvir (39) · Lopinavir (35) · lopinavir-ritonavir drug combination (34) · peginterferon alfa-2b (34) · Nevirapine (30)
GlaxoSmithKline (56) · Hoffmann-La Roche (56) · National Taiwan University Hospital (23) · University of California, San Francisco (23) · Kirby Institute (22) · University of Washington (21) · Germans Trias i Pujol Hospital (20) · Gilead Sciences (17) · National Institute of Allergy and Infectious Diseases (NIAID) (17) · Merck Sharp & Dohme LLC (16) · ViiV Healthcare (15) · Third Affiliated Hospital, Sun Yat-Sen University (14) · Fundacion SEIMC-GESIDA (13) · Bristol-Myers Squibb (12) · Emory University (12)
United States (371) · China (125) · Spain (104) · Canada (66) · South Korea (59) · Taiwan (58) · Brazil (46) · Germany (46) · Thailand (44) · United Kingdom (41) · Australia (40) · France (37) · Italy (37) · South Africa (36) · Puerto Rico (29)
Chen-Hua Liu, MD (9) · Bonaventura Clotet, MD,PhD (6) · Jia-Horng Kao, MD, PhD (6) · Shih-Jer Hsu, MD (6) · Cheng-Chao Liang, MD (5) · Colleen Kelley, MD, MPH (5) · Jun Cheng, M.D. (5) · Ming-Lung Yu, MD, PhD (5) · Raymond T Chung, MD (5)
PMID 41276263, PMID 24915612, PMID 28404091, PMID 28404092, PMID 15470215, PMID 19187608, PMID 21182232, PMID 22225814, PMID 22436845, PMID 23046671, PMID 23518903, PMID 28427875, PMID 29405329, PMID 32710245, PMID 41701614, PMID 15014185, PMID 19052126, PMID 19729084, PMID 20009522, PMID 20049753, PMID 21366801, PMID 22045673, PMID 22508412, PMID 22777097, PMID 23732904, PMID 24954675, PMID 25297720, PMID 25348661, PMID 26867206, PMID 29696665, PMID 30552056, PMID 30576085, PMID 30689258, PMID 32078808, PMID 33460002, PMID 33857679, PMID 34843068, PMID 35599306, PMID 37018493, PMID 37096802, PMID 38118022, PMID 39373164, PMID 40390028, PMID 42349783, PMID 10051494, PMID 10218526, PMID 10219064, PMID 10613747, PMID 10618544, PMID 11172138
2005 (7), 2009 (6), 2014 (4), 2019 (4), U01AI068632 (4), U01AI068636 (4), 2004 (3), 2008 (3), 2015 (3), 2016 (3), UM1AI068636 (3), R01AI145971 (2), R01HD068174 (2), R01MH072383 (2), 2017 (1)